Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Forte BiosciencesSTU:37T -0.53%42 PB Ratio is 14.36 as of Jul. 15, 2026. GuruFocus rates STU:37T with a GF Score™ of 42/100. The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Forte Biosciences ranks worse than 90.23% on this metric.
The historical rank and industry rank for Forte Biosciences's PB Ratio or its related term are showing as below:
STU:37T'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 14.3
Current: 14.3
During the past 7 years, Forte Biosciences's highest PB Ratio was 14.30. The lowest was 0.00. And the median was 0.00.
STU:37T's PB Ratio is ranked worse than 90.23% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs STU:37T: 14.30
During the past 12 months, Forte Biosciences's average Book Value Per Share Growth Rate was -42.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -53.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -48.30% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Forte Biosciences was -40.40% per year. The lowest was -53.30% per year. And the median was -51.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Forte Biosciences PB Ratio Related Terms
Forte Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Forte Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Forte Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forte Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forte Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Forte Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Forte Biosciences (STU:37T) has a PB Ratio of 14.36 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Forte Biosciences and its competitors. According to the industry distribution chart, Forte Biosciences ranks #1108 out of 1228 companies in the Biotechnology industry, placing it in the top 90.2%.
Is Forte Biosciences' PB Ratio too high?
Forte Biosciences' current PB Ratio is 14.36. The Biotechnology industry median PB Ratio is 2.90. Forte Biosciences' value of 14.36 is 396% above this industry median. Based on the distribution chart, Forte Biosciences ranks #1108 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Forte Biosciences has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' PB Ratio compare to AUTL and SGMT?
According to the Biotechnology industry distribution chart, Forte Biosciences ranks #1108 out of 1228 companies for PB Ratio. This places Forte Biosciences in the lower half of its industry. The industry median PB Ratio is 2.90. Forte Biosciences' value of 14.36 is 396% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Forte Biosciences's current PB Ratio of 14.36 is 396% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Forte Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Forte Biosciences's current PB Ratio is 14.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (STU:37T) has a current PB Ratio of 14.36. The current PB Ratio is 14.36 and 396% above the Biotechnology industry median of 2.90. Forte Biosciences' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Forte Biosciences (STU:37T), the current PB Ratio is 14.36 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
42GF Score
Get the complete analysis for STU:37T
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:37T has been successfully added to your 
